

DAILY NEWS

SEE THE DAILY SCHEDULE FOLLOWING PAGE 8



Practice-Changing, Paradigm-Shifting Clinical Trials in Urology

Exceptional, groundbreaking studies expected to change the day-to-day practice of urology.

11-11:20 a.m.
2:35-3:05 p.m.
Plenary, Hall D



Learning Lab

Flip the Script: Case Submissions
1-3 p.m.
Hall B, The Square



AUA Robotics Theater

Don't miss today's live narration of robotic procedure videos and a panel discussion.

Prostate
9:30 a.m.-11:30 a.m.

Reconstruction
1-3 p.m.

S&T Hall, Booth #117



Patient Perspectives

11:30 a.m.-1:30 p.m.
Plenary Foyer

AUA-2026
Washington, DC MAY 15-18

DAILY NEWS ONLINE



Scan the QR code to view more live coverage from AUA2026

The hidden cost of looking harder for cancer

Aggressive screening distorts survival statistics and fuels unnecessary treatment in asymptomatic patients.



Historically, cancer has been diagnosed in individuals showing symptoms. However, recent efforts to promote increased screening have resulted in more diagnoses among asymptomatic patients.

H. Gilbert Welch, MD, MPH, a general internist and cancer researcher at the Center for Surgery and Public Health at Brigham and Women's Hospital in Boston, used the annual Ramon Guiteras Lecture during Friday morning's Plenary to explore the concept of cancer "overdiagnosis."

"If you look harder for cancer, you find more," Dr. Welch said. "All medical students are taught that incidence is the true occurrence of disease, but it's not just that.

It's influenced by how hard we're looking for cancer."

Dr. Welch also clarified that increased screening results in more diagnoses. For some, this might suggest a higher prevalence of the disease and the necessity for extra measures. However, some of these cancers will be detected in asymptomatic individuals and may never lead to problems, much less death. As a result, the average patient tends to appear healthier as the number of diagnoses increases. This perceived improvement can be quite influential; it can also be quite misleading.

Dr. Welch used five-year survival rates to illustrate his point. He suggested that many physicians and public health professionals link higher survival with lower mortality, but this isn't always correct.

// If you look harder for cancer, you find more. All medical students are taught that incidence is the true occurrence of disease, but it's not just that. It's influenced by how hard we're looking for cancer."

—H. Gilbert Welch, MD, MPH

To better understand this, it's important to remember that survival rates are calculated by dividing the number of diagnoses by the number of patients alive at the time being examined. As diagnoses rise, the survival rate can increase even if the death rate stays the same.

To put this in perspective, the 10-year survival rate for melanoma skin cancer increased from 50% to nearly 100% between 1971

and 2018, yet the death rate remained unchanged. Conversely, the 10-year survival rate for lung cancer improved only slightly, but the death rate has halved.

These misleading figures impact not just health care providers but also shape popular culture. As diagnosis rates rise, more survivors share their stories. Furthermore, more people believe they owe their lives to a screening

Lecture continued on page 4

INSIDE

UPDATED RESULTS FROM THE POTOMAC TRIAL **3** THE ROLE OF EXTENDED LYMPH NODE DISSECTION **4**
QUESTION OF THE DAY **6** THE EXPANDING ROLE OF BIOMARKERS IN PROSTATE CANCER **12**

Focal One[®]
ROBOTIC FOCAL HIFU



Meet The Experts
FOCAL ONE BOOTH #1427



Permanent J-CODE: J9282



Zusduri™
(mitomycin) for intravesical solution

Learn


ABOUT ZUSDURI™
AND OUR RTGEL®
TECHNOLOGY AT
THE UROGEN®
BOOTH 2943

See you soon!



ZUSDURI™ is a trademark and UroGen® and RTGel® are registered trademarks of UroGen Pharma, Ltd.
© 2026 UroGen Pharma, Inc. All rights reserved.
US-ZUS-00275 02/26

Learn more about how
ZUSDURI may fit
into your practice at
ZUSDURI.com/hcp



Durvalumab + BCG continues to deliver in high-risk NMIBC

Longest-running NMIBC trial shows sustained disease-free survival benefit and delayed cystectomy at five years.



“These data clearly support one year of durvalumab with induction maintenance of BCG as a potential new treatment with high-risk NMIBC.”

—Neal Shore, MD

risk event. There was also a clinically significant delay in time to cystectomy: 14 months with BCG only versus 19 months with durvalumab + BCG, HR 0.63. The addition of durvalumab did not affect a patient’s ability to receive adequate BCG therapy

Dr. Shore noted that while median cystectomy-free survival has not yet been reached, the durvalumab cohort already shows a statistically significant improvement, HR 0.69.

Most patients in the trial had papillary tumors, and there was a reduction in high-risk disease recurrence or death across papillary subtypes, HR 0.56. The median OS has not yet been reached, but the survival trend continues to favor durvalumab, HR 0.80.

Adverse events (AEs) were common, with 88% of patients showing some sort of AE that could be related to treatment. About a quarter of AEs (23%) were grade 3-4, and 13% were serious. Similar numbers of AEs leading to discontinuation were likely due to durvalumab (16%) and BCG (15%). Some 27% of AEs were immune-mediated events.

“Immune-mediated adverse events are important for our colleagues to become comfortable with,” Dr. Shore said. “The most common things are thyroid events, followed by hepatic events and rash. The majority of these resolve with interruption, topical treatment and the potential use of steroids.” ●

Updated results from the POTOMAC trial show continued improvement in disease-free survival, overall survival and time to cystectomy with durvalumab plus bacillus Calmette-Guérin (BCG) in patients with high-risk, non-muscle invasive bladder cancer (NMIBC). With five years of follow-up and counting, POTOMAC is already the longest-running clinical trial in NMIBC.

“These data clearly support one year of durvalumab with induction maintenance of BCG as a potential new treatment with high-risk NMIBC,”

said Neal Shore, MD, medical director of the START Carolinas/Carolina Urologic Research Center in Myrtle Beach, South Carolina. “The safety of durvalumab plus BCG in the overall safety population and across papillary subgroups was consistent with the known safety profiles of BCG and durvalumab.”

Dr. Shore updated the efficacy and safety findings of POTOMAC in the first Practice-Changing, Paradigm-Shifting Clinical Trials presentation during Friday’s Plenary Session. Initial data were presented in 2025 and published in *The Lancet*.

Early high-risk disease recurrence is associated with worse outcomes in NMIBC, and BCG unresponsiveness is an accepted indication for radical cystectomy. The initial results showed that adding one year of durvalumab to BCG was associated with a significant improvement in disease-free survival (DFS), with a hazard ratio (HR) of 0.68 and a nonsignificant trend toward improved overall survival (OS).

Five-year data presented on Friday showed the same 32% improvement in DFS, along with an overall decline in the number of early high-risk events and a delay in time to the first high-

AUA 2026 | DAILY NEWS

The AUA Daily News is the official newspaper of AUA2026 and is published by Ascend Media.

AUA Staff

Darci Berliant
Heather Corkin
Elaine Garrison
Melissa Goodman
Kathleen Warshawsky

Ascend Media

Cindy Ratcliff, Editor and Writer
Timothy Nord, Senior Graphic Designer

© 2026 American Urological Association
1000 Corporate Blvd.
Linthicum, MD 21090
www.auanet.org

Ascend Media encourages and practices environmentally friendly printing, including recycled/recyclable paper and plant-based inks.

STREAM ON-DEMAND

Plenary Forums,
Instructional Courses
and much more!



SCAN QR CODE TO
ACCESS WEBSITE



Lecture

continued from page 1

test, serving as evidence of screening's success.

Of all specialties, Dr. Welch said he believes urologists understand the problem of overdiagnosis best and are taking steps to address it. For kidney cancer, they initiate active surveillance for small renal masses, and for prostate cancer, they make the case for active surveillance in low-risk disease.

"These approaches make use of what I call the diagnostic value of time. Not trying to decide something about phenotype at a single point in time, but instead, observing it over time and getting more data on growth. Time provides information," Dr. Welch said.

In terms of surveillance following treatment for curative intent, an analysis of 12 trials found no significant difference. Although recurrence markedly increases risk, knowing earlier doesn't extend patients' lives. ●

Updated trial refines role of extended lymph node dissection

More than 10 years of follow-up reveal improved outcomes with EPLND in patients with ISUP grade 3-5 prostate cancer.



Jean F.P. Lestingi, MD, PhD

The removal of pelvic lymph nodes is commonly performed during radical prostatectomy for prostate cancer. However, the use of extended pelvic lymph node dissection (EPLND) is controversial.

A phase 3 randomized trial evaluating EPLND versus limited pelvic lymph node dissection (LPLND) during radical prostatectomy for intermediate- and high-risk prostate cancer was published in 2021. During Friday's Practice-Changing, Paradigm-Shifting Clinical Trials in Urology session, Jean F.P. Lestingi, MD, PhD, assistant professor of urology at the Instituto de Cancer do Estado de Sao Paulo, presented updated data.

The trial enrolled 300 patients, randomized to EPLND (obturator, external iliac, internal iliac, common iliac and presacral nodes) or LPLND (obturator nodes). The primary endpoint was biochemical recurrence-free survival (BCRFS), and secondary endpoints included metastasis-free survival (MFS) and cancer-specific survival (CSS).

"As previously published, this randomized phase 3 trial did not demonstrate oncologic superiority of EPLND over LPLND among unselected intermediate- and high-risk prostate cancer patients," Dr. Lestingi said.

According to guidelines, clinicians should inform patients that pelvic

lymph node dissection can provide staging information but does not have consistently documented improvement in MFS, CSS or overall survival. However, recent research has suggested otherwise: One study reported a better MFS among patients randomized to EPLND, although there was still no statistically significant difference in BCRFS.

Dr. Lestingi and team continued to follow the patients in this phase 3 trial. At a median of 130.6 months, patients with biopsy International Society of Urological Pathology (ISUP) group grade 3-5 demonstrated a significant and sustainable benefit in BCRFS.

The study also looked at secondary treatments needed. In the ISUP biopsy grade 3-5 subset, the median time to radiotherapy was 43.7 months in the LPLND group and was not reached in the EPLND group. The median time to androgen deprivation therapy was 66.5 months in the LPLND group and was not reached in the EPLND group. These results suggest that the benefits seen for the more aggressive cancer type came from the surgical approach.

Based on these findings, Dr. Lestingi suggests that EPLND could be considered the standard of care in ISUP grade 3-5 patients undergoing radical prostatectomy. He also emphasized the need for guideline recommendations to take these updated data into account. ●



PRODUCT SPOTLIGHT

mediplus

Mediplus S-Cath™ System
Safer, more precise suprapubic catheterization

The Seldinger suprapubic catheter insertion kit

www.mediplusuk.com



American
Urological
Association

AUA JobFinder

AUA2026 CAREER FAIR

Meet with 50+ hiring
employers!

Sunday, May 17
10 a.m.-Noon
Located on Level 3
Ballroom pre-function #1

Snacks and drinks provided!

Presented by



**REGISTER
NOW!**

MORPHEUS® URODYNAMICS



Advanced



Video



Office

Precision. Integration. Expansion.

Connect with us at **AUA2026 Booth #4019 | Hall A**

GET SOCIAL!

Join the conversation online
#AUA2026



QUESTION OF THE DAY

What is one thing you've seen at AUA2026 that made you stop and think, "This will reshape urology over the next five years"?

I thought the session on endoscopic urethroplasty for recurrent recalcitrant bladder neck stenosis was absolutely fabulous. I have already looked it up to see how I can get the instruments.



Melanie Aube-Peterkin, MD
Montreal, Quebec, Canada

I think the technology will be what reshapes urology, and how the surgeon uses that technology. The engineering and the robotics will help shape it, but the real difference will come in how the surgeon implements and decides to use it.



João Ernesto Aldred Pinto Filho, MD
Rio de Janeiro, Brazil

I think one thing I noticed that is going to shape urology down the road is that we are starting to extend the management of bladder conditions even into primary care, which is interesting. They are trying to identify misconceptions about the treatment of urinary urgency and complications that patients typically present to primary care, so maybe we can start intervening at the first place patients come with these concerns.



Vandanaa Jayaprakash,
medical student
Richmond, Virginia



Visit us at
AUA2026 Booth #1843

Experience
**High-Performance
Aspiration**



Scan the QR code
for more information about
the CVAC System at AUA2026

The only all-in-one high performance aspiration system for the treatment of kidney stones.

Microjet Irrigation

Targeted jets fluidize stone and debris.

Simultaneous Flow

Continuous irrigation and aspiration in parallel.

Large Outflow Lumen

Highly efficient evacuation of dust and fragments.

Leave no stone behind.



www.calyxo.com


© 2026 Calyxo, Inc. | MAC00324.A

Medtronic

It's here. A new status quo.

Hugo™ Robotic-Assisted Surgery System.
Now available in the United States.

Learn more at Medtronic booth #1604.



Join us for a Hugo™ RAS
system semi-live surgery

Presented by Dr. Zack McDowell
Moderated by Dr. James Porter

Friday, May 15
9:30 - 10:15 a.m.

AUA Product Theater | Booth #2701

DON'T MISS

How I do it: Robotic prostatectomy video case review

Presented by Dr. Ronney Abaza

Sunday, May 17
11:30 a.m. - 12:30 p.m.
Medtronic Booth #1604

medtronic.com/hugo





American
Urological
Association

THE SQUARE

ENGAGE | EXPLORE
RELAX | REFUEL

Registration

AQUA Registry and
Census Booth

AUA Café

AUA Store

Education Central

Learning Lab

Member Central


Publications Booth

Select Square offerings
have expanded to the
**Plenary foyer, located
on level 2:**

The Urology Care
Foundation

Advocacy Booth

Patient Perspectives



WHICH OF YOUR PATIENTS WITH RCC ARE AT HIGHER RISK OF RECURRENCE AFTER SURGERY?

According to a retrospective, observational analysis of EMR data from 439 patients with RCC at higher risk for recurrence post nephrectomy from 2012 to 2021

More than half of patients in this analysis experienced recurrence¹

51%

experienced recurrence

34%

experienced death

- Among patients with a recurrence, 85% had distant metastasis.¹

Analysis Population¹:

- Eligible patients were adults (aged ≥ 18 years) diagnosed with nonmetastatic RCC between January 1, 2012 and December 31, 2017 to allow for the potential of a 3-year follow-up period.
- Patients at higher risk for recurrence included: T2, N0, M0 with grade 4 cells or sarcomatoid histology; T3, N0, M0; T4, N0, M0, or any T stage with N ≥ 1 , M0.
- **Median follow-up duration was 39 months.**

Analysis Limitations¹:

- Data were sourced from principally community oncology practices, representing diverse practice locations in both rural and urban centers, within the US.
- Data from these practices were provided to the ConcertAI Oncology Dataset. Therefore, imaging assessments, procedures, or visits outside this network may not have been captured.

EMR = electronic medical record; M0 = no distant metastasis; N0 = no regional lymph node metastasis; RCC = renal cell carcinoma; T2 = tumor >7 cm in greatest dimension, limited to the kidney; T3 = tumor extends into major veins or perinephric tissues, but not into the ipsilateral adrenal gland and not beyond Gerota's fascia; T4 = tumor invades beyond Gerota's fascia (including contiguous extension into the ipsilateral adrenal gland).


References: 1. Karam JA, Bhattacharya R, Ogbomo A, et al. Real-world study on the characteristics, post-nephrectomy journey, and outcomes of patients with early-stage renal cell carcinoma based on risk groups. *Cancer Med.* 2024;13(11):e7247. doi:10.1002/cam4.7247 2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines[®]) for Kidney Cancer V.1.2026. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed July 28, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. 3. Sundaram M, Song Y, Rogerio JW, et al. Clinical and economic burdens of recurrence following nephrectomy for intermediate high- or high-risk renal cell carcinoma: a retrospective analysis of Surveillance, Epidemiology, and End Results–Medicare data. *J Manag Care Spec Pharm.* 2022. doi:10.18553/jmcp.2022.22133 4. Sundaram M, Song Y, Rogerio JW, et al. Supplementary Materials for: Clinical and economic burdens of recurrence following nephrectomy for intermediate high- or high-risk renal cell carcinoma: a retrospective analysis of Surveillance, Epidemiology, and End Results–Medicare data. *J Manag Care Spec Pharm.* 2022. doi:10.18553/jmcp.2022.22133



Learn more about how patients who have T3 and T4 tumors may be at greater risk of their cancer returning after surgery.²⁻⁴



SCIENCE & TECHNOLOGY HALL MAP AND EXHIBITOR LIST



A-D

A&E Endoscopy.....	3608
AbbVie.....	2826
Accord BioPharma.....	3161
ACE Medical Company.....	3660
AcuityMD.....	513
Advanced Medical Designs.....	1417
Advanced Endoscopy Devices.....	813
AdvantageTrust.....	1454
Agility.....	742
Akina Pharmacy.....	511
ALDAVER Inc.....	3643
Alembic Therapeutics, LLC.....	1255
All Star Healthcare Solutions.....	2568
Alton (Shanghai) Medical Instruments Co., Ltd.....	2861
Ambu Inc.....	3933
America Medic & Science, AMS.....	443
American Medical Endoscopy.....	4027
AmeriPath.....	610
AnazaoHealth.....	3064
Andromeda Surgical.....	2563
AngioDynamics.....	3605
Angiogenesis Analytics BV.....	117
Anhui Happiness.....	555
Answers in CME.....	208
Artera.....	4008
Asociación Urológica de Centroamerica y Caribe (AUCA).....	3569
Astellas Pharma US.....	1543
AstraZeneca.....	3315
Aulea Medical Inc.....	843
Avation Medical.....	615
Avenda Health.....	343
Axogen.....	2567
Aya Locums.....	2466
Ballad Health.....	605
Bayer.....	943
Baylor Scott & White Health.....	3861
BD.....	2753
Best Medical International.....	2951

BIMEDIS.....	1154
Biobot Surgical U.S. Inc.....	3164
BioProtect.....	3815
Blue Earth Diagnostics, Inc.....	3833
BLUERAY MEDICAL.....	406
BlueWind Medical.....	4127
Boston Scientific.....	2443
Bright Uro.....	3715
Bristol Myers Squibb.....	2667
Butterfly Medical.....	448
Calmoseptine, Inc.....	3060
Calyxo, Inc.....	1843
Canadian Urological Association (CUA).....	3662
Candel Therapeutics.....	307
Carbon (Shenzhen) Medical Device Co., Ltd.....	3261
CareTech Human Inc.....	2654
Caris Life Sciences.....	4232
Case Recruiters, Inc.....	1115
CBSET Inc.....	2465
CG Oncology Inc.....	3051
Chengdu Daxan Innovative Medical Tech.Co.,Ltd.....	2862
CIVCO Medical Solutions.....	2365
Clarity Pharmaceuticals.....	4106
Class Medical.....	2559
Cleveland Clinic.....	1551
Coloplast Corp.....	3527
CompHealth.....	3657
CompuGroup Medical.....	405
Complink Healthcare Solutions.....	349
Confederación Americana de Urología.....	3667
Cook Medical.....	3143
Copper Medical Technology Co.,Ltd.....	3466
Cortechs.ai.....	2968
Cruzbike, Inc.....	2369
CS Surgical, Inc.....	808
DAVA Oncology.....	646
Dawell Medical LLC.....	3468
Decipher Urologic Cancers, Subsidiary of Veracyte.....	3405

Del Medical.....	619
Dendreon Pharmaceuticals LLC.....	3851
Designs for Vision, Inc.....	2761
Digital Science Press/UroToday.....	3661
Dongguan ZSR Biomedical Technology Co., Ltd.....	2455
Dornier MedTech.....	3343
Dyne Medical Group Inc.....	3364

E-I

Edge Life Technologies LLC.....	4006
Eigen Health.....	4033
Electro Medical Systems SA.....	3133
ELMED Medical Systems.....	647
Emano Flow.....	2467
eNawi.....	2869
Endourological Society, Inc.....	245
enGene.....	907
Epic Physician Staffing.....	407
Erlanger Health.....	3062
Esaote North America.....	3646
European Association of Urology.....	4059
Exact Imaging.....	449
Farco-Pharma GmbH.....	644
Fellow.....	1119, 4020
Ferring Pharmaceuticals Inc.....	2626
Filax Medical AG.....	1055
Firefly Global.....	1516
Focal One.....	1427
Focalyx.....	1109
Fox Chase Temple Urologic Institute.....	2464
Francis Medical.....	3743
Freedom+ INCONTINENCE & PELVIC HEALTH.....	3961
Fujifilm.....	319
GE HealthCare.....	2643
Gemini Medical Technologies.....	433
GEOTEK Medical USA LLC.....	2960
Gitler &.....	855
Give Legacy, Inc.....	115
Global Medical Endoscopy.....	3907

GoPath Diagnostics.....	3515
GOTOP Medical, Inc.....	3547
Grit Medical.....	2865
Guangzhou Potent Medical Equipment Joint-Stock Co., Ltd.....	3461
Hangzhou Hawk Optical Electronic Instruments Co.,Ltd.....	3648
Hayes Locums.....	3644
HealthTronics, Inc.....	3061
Himaging Technology (Shanghai) Co., Ltd.....	956
HistoSonics.....	3307
Human Hydrology Devices.....	2664
Hunan Endoso Life Technology Co.,Ltd.....	342
Hunan Vathin Medical Instrument Co., Ltd.....	3749
ImmunityBio, Inc.....	1513
InnoCare Urologics.....	2562
Innovex Medical.....	3251
Inova Health.....	2967
inReach Health.....	2666
Insight Medbotics Inc.....	2656
Intermountain Health.....	247
Intuitive Surgical.....	424
iO Urology.....	2554
Irrisept.....	1745
IsoPSA.....	3369, 4111
IVUmed.....	3131

J-M


Japanese Urological Association.....	3565
Jiangsu Sanwe Medical Science and Technology Co., Ltd.....	2860
JIASHAN HONGFENG.....	2662
Johnson & Johnson.....	1927
KARL STORZ Endoscopy.....	1127
Keenova Therapeutics.....	1243
Kettering Health.....	214
Kolis.....	743
Laborie Medical Technologies.....	3726
Lantheus.....	915
Lazarus 3D.....	3232

Lee Memorial Health System dba Lee Health.....	217
LEXION Medical.....	219
Lilium Otsuka Co., Ltd.....	4007
LINA Medical.....	1747
Litholyte Health.....	3165
LocumTenens.com.....	612
LP Surgical Fibers.....	543
LSI SOLUTIONS.....	3168
Lumea.....	547
Lynx Dx.....	1209
M.A.S. Medical S.r.l.....	3857
MacroLux Medical Technology Co., Ltd.....	3651
Main Line Health.....	111
Male From Home.....	607
Mcube Technology Co., Ltd.....	916
MDxHealth.....	3327
Med Fibers, Inc.....	3351
Meda CO., LTD.....	2961
MEDANNOT s.r.o.....	206
Medax USA.....	3367
MEDICA S.p.A.....	409
Medical Expo Supplies.....	3650
Medicus Healthcare Solutions.....	705
Medifix Inc.....	3065
MEDIFLEX.....	4135
Mediloupes.....	316
Mediplus.....	643
MEDiThings.....	2564
MediView.....	308
MEDNOVA MEDICAL.....	3555
Medpro.....	806
Medtronic.....	1604
Medworks.....	2763
MegaWatt Lasers, Inc.....	1354
Memorial Hermann Health System.....	3368
Mendaera.....	507
MenHealth.....	3066
Menovex.....	713
Merck & Co., Inc.....	927
Merit Medical Systems, Inc.....	4053

2161
Devi
Tech T

2159
Philips

Main
AUA S



Miconvey Technologies Co., Ltd.....	2557
Microsurgery Instruments Inc.....	3913
Mid-Atlantic Section of the AUA	248
MIM Software, a GE HealthCare Company	2661
Minerva Health Solutions Inc.....	2658
MiRNA Scientific, Inc.	4012
ModMed.....	942
Molecular Imaging Services, LLC	351
Moonstone Nutrition	4011
Multiphze LLC	3549
MV.Health.....	3859
myPelvicBra®.....	755
Myriad Oncology.....	3511

N-R

Nanchang WOEK Medical Technology Co., Ltd.....	2555
Nanova Biomaterials Inc.....	554
Natera	3269
Neuspera Medical, Inc.	3911
New Wave Endo-Surgical.....	3545
New York Section Of The American Urologic Association Inc.....	243
NextGen Healthcare	4013
NinoMed.....	1842
Nitra	504
Nonagen Bioscience Corp.....	709
North Central Section of the AUA, Inc.	355
Northeastern Section of the AUA, Inc.	356
Northern Litho.....	4043
Northwell Health.....	318
Novartis	527
Novoglan Phimosi s Treatments	3265
Olympus America Inc.	3843
OncoAssure.....	4108
OPKO Health, Inc.....	1743
Oruba Technology & Innovation	2463
OTU Medical Inc.....	3561
P4 Diagnostix.....	3551
Pacific Edge Diagnostics USA Ltd.....	3707
Pathnostics.....	3129

Pathomiq	109
PathRight Medical.....	4114
Patriot Laser LLC	1054
PD Labs Compounding Pharmacy	4226
Pelvic Wave/React.....	955
Peruvian Society of Urology	3669
Pfizer Oncology	1627
PHARMATOKA	655
Philips.....	2159
Photocure	3227
Piedmont Healthcare	346
Porter Instrument	1846
PracticeLink.....	1409
Predicine.....	3756
Prisma Health - Provider Recruitment.....	2963
Procept Biorobotics	2342
Profound Medical.....	413
Promaxo	4149
Prometheus Group, The	4019
Promis Dx	2965
Prostatype Genomics Inc	744
Protara Therapeutics Inc.....	749
ProVerum.....	3615
Providence	1455
PSS Urology	455
Pusen USA.....	3427
Quanta System SPA.....	1327
Quibim.....	847
Relmada Therapeutics.....	3949
ReSheyP.....	1256
Revive Rx Compounding Pharmacy.....	454
RG Medical	3469
Rheme GmbH.....	3757
Richard Wolf Medical Instruments Corporation.....	3233, 3234
Rigicon	1143
Rocamed.....	1309
Rocoto	4057
Rose Micro Solutions LLC	1443, 3230
RosmanSearch	1216
RZ Medizintechnik GmbH.....	216

S-T

Sagent Specialty	4126
SamanTree Medical	310
Samsung.....	3360
Sciteck Diagnostics, Inc.....	3957
Seplou Medical	3507
SH MEDICAL CORP	4016
Shanghai Raykeen Laser Technology Co., Ltd.	3357
Shanghai SeeGen Photoelectric Technology Co.,Ltd.	3652
ShenZhen Trious Medical Technology Co.,Ltd	3462
Siemens Healthineers	1542
Signati Medical, Inc.	1445
Skin-Gen	4230
Skyseeker	309
Sociedad Argentina de Urologia.....	3665
Sociedad Mexicana de Urologia.....	3668
Sociedade Brasileira de Urologia (SBU)	3664
Société Internationale d'Urologie (SIU).....	707
Society of Government Service Urologists (SGSU).....	244
Society of Urologic Nurses and Associates (SUNA)	246
Sonablate Corp	826
SonoMotion, Inc.....	1508
Sonostar Technologies Co., Limited	3553
Sontec Instruments.....	1651
Sony Electronics	3958
Soundable Health.....	1411
South Central Section of the AUA, Inc.....	355
Southeastern Section of the AUA, Inc.	356
SRS Medical Corp.....	2358
St. Luke's University Health Network.....	213
STIMULI TECHNOLOGY / TENSII+	4133
Strauss Surgical USA	3927
Stryker Endoscopy	313
Sumitomo Pharma America, Inc.	2326
Surgical Science	3127
SurgiTel.....	606

Sutter Health - Physician & APC Recruitment.....	1356
Synergy Health Partners.....	3760
SZ HugeMed MED TECH DEV CO., LTD.....	3457
Tandem.....	4228
Teleflex Interventional Urology.....	2043
Teleflex Surgical	209
Telix Pharmaceuticals (US), Inc.....	1215
Tempus AI	642
Test Labs.....	1355
The HRT Club	613
The MetroHealth System.....	3268
The Permanente Medical Group.....	1518
The Surgicalist Group	3659
Theralase Technologies	3169
Theralogix	704
Timm Medical	3959
Tolmar Inc.....	2927
Trinity Medical Solutions, LLC.....	4110
Tyra Biosciences	656

U-Z

UC-CARE	719
United Endoscopy	3917
United Medical Systems.....	3732
Universal Health Services (UHS)	3960
University Compounding Pharmacy.....	4143
University of Miami Health System.....	1056
Uramix, Inc.....	3363
URO-1, Inc	1413
URO360.....	3365
UroGen Pharma, Inc.	2943
UroGuard.....	912
Urologic Association of Asia.....	3567
Urological Association of Physician Associates (UAPA)	250
Urology Alliance	819
Urology Health Store	1214
UrologyLocums.com	3606
Uromedica, Inc.	1512
UroNova Pharmaceuticals, Inc.....	3125

UVA Health	2468
Valencia Technologies.....	4117
Vaniam Group.....	946
Vanta Diagnostics.....	3267
Vascular Technology Inc.....	517
VasectomyStore.com	609
Vedkang Medical Science & Technology.....	2556
Verana Health	2469
Verathon	807
Verity Pharmaceuticals, Inc.....	2867
Verity Pharmaceuticals, Inc.....	2966
VersaWell, Inc.....	107
Veterans Health Administration.....	712
Viemerse.....	2767
VirtaMed.....	754
Viscera Health	2459
Vitacon US.....	506
Vortex Imaging.....	4049
Wasatch Medical Specialties	748
Weatherly Healthcare	3956
Well Lead Medical Co. Ltd.	3451
Wellspect HealthCare	3067
Wellstar Health System.....	3068
West Virginia University Health System WVU Medicine	1155
Western Section American Urological Association Inc (WSAUA)	242
Wren Laboratories.....	2964
Xaga Surgical AB.....	2863
Xialla	456
Xuzhou Kaixin Electronic Instrument Co., Ltd.....	3464
Xytex	3758
Yigao Medical Technology Co.,Ltd.....	3264
Zenflow, Inc.....	3809
Zhejiang Geyi Medical Instrument Co., Ltd.....	2668
Zimmer MedizinSystems	804

VOICES & VIEWS

Join the conversation on Instagram, Facebook and X. #AUA2026



Kyle A. Richards
@Uro_Rich

Just wrapped up our inaugural non-invasive bladder cancer course with faculty Betsy Koehne, Keli Syse (NP), and Peter O'Donnell (med onc).

Great cases and discussion from our very interactive audience and we all learned a lot!
@WiscUroOnc @wiscurology @AmerUrological #AUA2026

Jane K. Nguyen, MD, PhD
@JaneNguyen44

Full house at the PD03 podiums! ★ Super star ★
@NicolasSoputro #SPARC #AUA2026
@drjkaouk @CleClinicUro @BradGillMD



Mack Roach III, MD

The expanding role of biomarkers in prostate cancer

Experts examine the rapid rise of PSMA PET, genetic testing and novel biomarkers.

PSA, the first biomarker in prostate cancer, has been part of patient care for decades.

Use of PSMA PET for staging has skyrocketed from single digits in 2021 to over 50% currently. Trials for biomarkers, biomarker-based imaging, germline mutation testing and tumor somatic testing are on the rise. Prostate cancer guidelines increasingly incorporate novel biomarkers for potential clinical consideration.

“Biomarkers are something that everyone who is taking care of prostate cancer patients needs to be aware of,” said Mohammad Minhaj Siddiqui, MD, professor of surgery and chief of urology at the University of Maryland School of Medicine and chief of urology at Maryland VA Healthcare System. He moderated a Focus On session Friday afternoon exploring the current state of biomarkers, MRI and PSMA PET imaging in prostate cancer.

Biomarkers are molecules in body fluids or tissues that can indicate a normal or abnormal biological process. They can be used alone or in combination with different imaging

modalities and other clinical measures to help diagnose or guide management decisions.

“We have biomarkers that have been shown in multiple studies to improve the ability to detect high-grade cancer,” said Simpa S. Salami, MD, MPH, associate professor of urology at the University of Michigan School of Medicine.

There are few direct comparisons between biomarkers, and many need further validation, he added, but diagnostic performance seems to be similar. Current biomarkers can confirm diagnosis with up to 30% fewer biopsies.

But not all widely used biomarkers have been well validated. Black patients, for example, are known to have lower electroretinogram (ERG) expression, which limits the utility of ERG-based tests.


MRI improves the detection of high-grade prostate cancer but should not eliminate surveillance biopsy. PSMA PET can facilitate staging before treatment.

“I use MRI and PET every day when I’m designing radiation-targeted areas,” said Mack Roach III, MD,

professor of radiation oncology and urology at the University of California, San Francisco. “It took us a long time to understand PSA, and it’s going to take us a long time to figure out what to do with all these biomarkers and a lot of validation.”

Multiple new agents have been approved for prostate cancer with multiple mechanisms and indications. Many are being moved into earlier, hormone-responsive settings without clear guidance. PSMA PET imaging is commonly used to diagnose, classify and track disease, also without clear guidelines.

Prostate Cancer Working Group 4 (PCWG4) is moving toward more evidence-based biomarker criteria and trial designs to optimize approaches for those who are most likely to benefit, said Michael A. Carducci, AEGON professor in prostate cancer research at the Hopkins Kimmel Cancer Center. PCWG4 is proposing a new indications model and new terminology, as well as specific approaches to the use of genetic testing and genomic evaluation to tailor treatment for PARP inhibitors and other agents. ●




Jack Loomer
@jackloome00

What a pleasure to present my research “County-Level Poverty as a Predictor for Prostate Cancer Mortality in Mississippi” at #AUA2026! Thank you to @UMMCnews and the John D. Bower School of Population Health!

GOLDSTEIN MICROSPIKE™

Approximator Clamps for
Vasovasostomy and Vasoepididymostomy

- Ends clamp slippage.
- Will not damage mucosa.
- Can be adjusted and locked in any position.
- Folds in two directions to facilitate anterior and posterior wall anastomoses.
- Can be stabilized by attaching a hemostat or needle holder.



Marc Goldstein,
MD, DSc (hon), FACS.
Matthew P. Hardy Distinguished
Professor of Reproductive
Medicine and Urology Senior
Scientist, Population Council
Surgeon-in-Chief, Male
Reproductive Medicine and
Surgery Cornell Institute for
Reproductive Medicine Weill
Cornell Medical College of
Cornell University New York-
Presbyterian Hospital/Weill
Cornell Medical Center

assi
ACCURATE SURGICAL & SCIENTIFIC INSTRUMENTS®
For diamond perfect performance®

accurate surgical & scientific instruments corporation
800.645.3569 • 516.333.2570 • fax: 516.997.4948
west coast: 800.255.9378 • Info: assi@accuratesurgical.com
Orders: orders@accuratesurgical.com • www.accuratesurgical.com

Not all ASSI products shown in our literature or on our website are available for sale in Canada



PLUVICTO[®]

lutetium Lu 177 vipivotide tetraxetan
INJECTION FOR INTRAVENOUS USE

FDA APPROVED FOR MORE PATIENTS



SCAN TO VISIT
[PLUVICTO-HCP.com](https://pluvicto-hcp.com)



Not actual patients.

 **NOVARTIS**

Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936-1080

© 2025 Novartis



PLUVICTO[®]


lutetium Lu 177 vipivotide tetraxetan
INJECTION FOR INTRAVENOUS USE

8/25

FA-11488958

AUA 2026


Washington, DC MAY 15-18



TRANSURETHRAL INTRAOPERATIVE PROSTATE POSITIONING

Precise, Reliable
Control During
Prostatectomy

Enables Dissection with
"Tissue Under Tension"



SSOLUTIONS®

BOOTH 3168

THE
microINVASIVE
SURGERY COMPANY

FACILITATE VISUALIZATION, SUTURE PLACEMENT, GRAFT DELIVERY




JNW URTRAC®




GENTLEGUIDE™

AUTOMATE SUTURING

ELIMINATE HAND-TYING KNOTS



RD® & RD180®




Ti-KNOT®

TRANSURETHRAL RECONSTRUCTIVE SURGERY

Durable Relief for
Bladder Neck Stenosis
& Urethral Strictures

No Skin Incision
Buccal Mucosa Grafting



INTRODUCING
JNW MITUS™

CoralView™
Ureteroscope



BubbleView™ C50-C
Cystoscope



CoralWell™
Access Sheath



OLYMPUS

Single-use Digital Flexible Endoscopes

High-quality visualization, optics, and maneuverability are within your reach and control.

Introducing the BubbleView™ Single-use Flexible Cystoscope, the CoralView™ Single-use Ureteroscope, and the CoralWell™ Single-use Access Sheath, a portfolio of devices used to access and visualize the bladder, urinary tract and kidneys to treat a broad range of urological conditions with confidence.

Visit **Booth #3843** to learn more or scan here to attend one of our AUA2026 Hands-on Workshops.



For safe and proper use follow the manufacturer's instructions for use handling, operating, and reprocessing of the product. Do not use for any purpose other than its intended use. If used or handled in an improper manner, there is a risk of patient and/or operator injuries, burns, infections, bleeding, and/or perforation, and/ or equipment damage.

Olympus is the distributor for MacroLux Medical Technologies Co, Ltd.